Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27630900 | 0.79 | GCGR (0.46) | KMT2ANPC1RAB9AMEN1NOX1 | |
| SCHEMBL3276928 | 0.79 | MAPK14 (0.53) | KMT2ASCN4ANPC1RAB9AMEN1 | |
| SCHEMBL27630953 | 0.79 | DYRK1B (0.45) | KMT2ASCN4AXDHRAB9AMEN1 | |
| SCHEMBL701773 | 0.77 | XDH (0.49) | KMT2AXDHRAB9AMAPTKDM4E | |
| SCHEMBL411907 | 0.77 | GSK3A (0.43) | KMT2ASCN4AXDHNPC1RAB9A | |
| SCHEMBL702632 | 0.77 | KMT2A (0.49) | KMT2ASCN4AXDHNPC1RAB9A | |
| SCHEMBL411698 | 0.75 | TUBB4A (0.56) | KMT2AMEN1MAPTKDM4ETP53 | |
| SCHEMBL702859 | 0.75 | IDO1 (0.43) | KMT2ASCN4AXDHNPC1RAB9A | |
| SCHEMBL703856 | 0.74 | NPC1 (0.55) | KMT2ANPC1RAB9AMAPTKDM4E | |
| SCHEMBL411388 | 0.74 | TUBB4A (0.54) | KMT2AMEN1MAPTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-12-19 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1919881-B1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
| US-20100279410-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2010-11-04 | — | — | US | disclosed |
| US-7781462-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | SYNTA PHARMACEUTICALS CORP. | 2010-04-15 | — | — | US | disclosed |
| EP-2059250-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Synta Pharmaceuticals Corporation (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1919881-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008033449-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| WO-2007014198-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | KMT2A 2808/4885SCN4A 3595/4885XDH 4194/4885 |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | KMT2A 2808/4885SCN4A 3595/4885XDH 4194/4885 |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | FLT4, FLT1, TEK | KMT2A 3944/4885SCN4A 4455/4885XDH 1109/4885 |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | KMT2A 2808/4885SCN4A 3595/4885XDH 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.